ClinicalTrials.gg
RecruitingNCT07687069Updated Oct 9, 2026

ESPB Versus Intravenous Lidocaine for Pain After Mastopexy

An interventional study of Ultrasound - guided Erector Spine Plane Block (ESPB) and Intraoperative intravenous lidocaine infusion in Breast Hypertrophy, sponsored by Centre of Postgraduate Medical Education. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Centre of Postgraduate Medical Education · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Elective breast reduction surgery is associated with moderate-to-severe postoperative pain and a risk of developing chronic postsurgical pain. Enhanced Recovery After Surgery (ERAS) protocols and the Procedure-Specific Postoperative Pain Management (PROSPECT) guidelines emphasize the importance of multimodal analgesia to reduce pain, minimize opioid consumption, and accelerate functional recovery following surgical procedures, including breast surgery.

The erector spinae plane block (ESPB) has demonstrated effectiveness in breast reduction surgery by reducing postoperative pain intensity, perioperative opioid and non-opioid analgesic consumption, and improving patient satisfaction and recovery time. Furthermore, the use of ESPB has been associated with a reduced incidence of postoperative nausea and vomiting. ESPB is performed with the patient in the sitting position and involves ultrasound-guided identification of the vertebral transverse processes on the side of the block, typically in the interscapular region, followed by the injection of approximately 20 mL of local anesthetic adjacent to the transverse process. When required, the procedure is performed bilaterally at the same vertebral level. ESPB is considered one of the simplest regional anesthesia techniques to perform.

Intravenous lidocaine infusion has been shown to significantly reduce opioid requirements and postoperative pain intensity across a wide range of surgical procedures, particularly in abdominal and breast surgery. Moreover, intraoperative lidocaine infusion has been associated with a reduced risk of chronic postsurgical pain following breast surgery.

This study was designed to investigate whether intraoperative intravenous lidocaine infusion is non-inferior to ESPB in reducing postoperative pain and improving the quality of recovery following non-oncological breast reduction surgery. Intravenous lidocaine infusion may provide analgesic efficacy and recovery outcomes comparable to those achieved with ESPB, thereby representing a less invasive alternative within a multimodal analgesic strategy.

Read the detailed description

High-quality evidence supports the effectiveness of the erector spinae plane block (ESPB) in reducing postoperative pain following both non-oncological breast reduction surgery and oncological breast reconstructive procedures. In one of the prospective studies bilateral ESPB reduced strong opioid consumption during the first 24 postoperative hours by approximately 50%, from nearly 14 mg to 7 mg of morphine equivalents, while also significantly decreasing patient-reported pain intensity at all assessed time points during the first postoperative day. These findings demonstrate the analgesic efficacy of ESPB compared with standard care without regional anesthesia.

An accompanying editorial highlighted both the methodological quality of the study and the reliability of its findings, while noting that breast reduction surgery is not typically associated with severe postoperative pain. This observation is indirectly supported by the reported opioid requirements, as a total consumption of 14 mg of morphine during the first postoperative day is relatively low, whereas a reduction of approximately 6-7 mg, although statistically significant, may be of limited clinical relevance. The editorial further suggested that, despite its excellent safety profile, bilateral ESPB may be considered unnecessary by some clinicians when postoperative pain can be adequately controlled using pharmacological multimodal analgesia without the need for strong opioids.

Intraoperative intravenous lidocaine infusion is a well-established component of contemporary anesthetic practice and is widely used within multimodal analgesic protocols. A meta-analysis including twelve high-quality studies of oncological breast surgery demonstrated beneficial effects of intravenous lidocaine on both intraoperative and postoperative opioid consumption, as well as a reduction in the incidence of chronic postsurgical pain.

Based on the available evidence, this study was designed as prospective randomized non-inferiority trial to determine whether intraoperative intravenous lidocaine infusion provides postoperative pain control and quality-of-recovery outcomes comparable to those achieved with ESPB in patients undergoing non-oncological breast reduction surgery.

The study will include patients of the Department of Plastic, Reconstructive and Aesthetic Surgery, Centre of Postgraduate Medical Education, W. Orlowski Hospital, Warsaw, Poland, aged 18-75 years, American Society of Anesthesiology (ASA) physical status I-III, scheduled for elective breast reduction for non-oncological indications.

During the pre-anesthetic assessment or following hospital admission on the day preceding surgery, patients will receive detailed information about the study and a written informed consent form. They will have the opportunity to ask questions and receive comprehensive answers regarding study participation. Signed consent forms will be collected on the morning of surgery.

Participants will be randomly assigned to one of two study groups:

Erector Spine Plane Block (ESPB) Group: Bilateral ESPB performed before induction of general anesthesia using 20 mL of 0.25% bupivacaine on each side.

Lidocaine (LIDO) Group: Intravenous lidocaine administered before induction of anesthesia as a bolus of 1.5 mg/kg over 10 minutes, followed by a continuous infusion at 1.5 mg/kg/h until completion of surgery.

Randomization will be performed using the randomizer.org website with a 1:1 allocation ratio.

Allocation concealment will be achieved using sequentially numbered opaque sealed envelopes. The envelope corresponding to the participant's randomization number will be opened on the day of surgery before the patient arrives in the operating room. Group allocation information will be communicated only to the anesthesiologist responsible for perioperative management.

Patient data will be recorded in a secure database inaccessible to unauthorized individuals. The following variables will be collected:

  • Demographic data: age, height, body weight, ASA physical status, comorbidities, smoking status and other substance use, and type of surgical procedure.
  • Surgical data: intraoperative fluid therapy, duration of surgery, estimated blood loss, and weight of resected breast tissue.
  • Intervention-related data: amount of study medication administered and perioperative adverse events commonly associated with general anesthesia, including hypotension and bradycardia requiring vasoactive treatment.

Upon arrival in the operating room, standard monitoring will be initiated and prophylactic antibiotic administration commenced according to institutional perioperative antibiotic prophylaxis protocols.

ESPB Group: Bilateral ESPB will be performed before induction of anesthesia. LIDO Group: Patients will receive an intravenous lidocaine infusion as described above.

General anesthesia will be induced and maintained according to institutional standards using opioids and anesthetic agents at the discretion of the attending anesthesiologist. Maintenance of anesthesia will be achieved with sevoflurane.

Postoperatively, all patients will receive standardized multimodal analgesia consisting of paracetamol 1 g every 6 hours, metamizole 1 g every 6 hours, and dexketoprofen 50 mg intravenously three times daily. If analgesia is insufficient, an opioid buprenorphine 0.3 mg will be administered intravenously or intramuscularly, with repeat doses permitted every 2 hours as needed. Pain intensity will be assessed with Numeric Rating Scale (NRS) (0-10, 0 indicating no pain and 10 worst pain imaginable). NRS score >3 will indicate the need for opioid administration. Additional intravenous boluses of 0.3 mg may be administered for breakthrough pain.

Pain intensity will be assessed during the first 48 postoperative hours using the NRS at rest and during coughing at predefined time points: 2, 4, 8, 24, and 48 hours after surgery.

Total opioid consumption during the first 24 postoperative hours (expressed as cumulative buprenorphine dose) and time to first opioid administration will also be recorded.

Before hospital discharge, patients will be asked to complete the validated Polish version of the Quality of Recovery questionnaire - 15 (QoR-15).

Assessment of Chronic Postsurgical Pain Patients will be contacted by telephone at 1, 3, and 6 months after surgery and asked about the presence of persistent pain in the surgical area.

If pain is reported, patients will be asked to assess its intensity using the NRS (0-10) and its neuropathic characteristics using the Douleur Neuropathique 4 (DN4) questionnaire. A DN4 score of ≥4 will be considered indicative of neuropathic pain.

02

Conditions studied

  • Breast Hypertrophy

Keywords

  • breast reduction
  • postoperative pain
  • erector spine plane block
  • lidocaine
  • pain modulation
03

In context

Gigantomastia

26 studies on the registry are indexed under Gigantomastia; 5 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 19 interventional studies indexed under Gigantomastia.

Browse Gigantomastia studies →

Lead sponsor

Centre of Postgraduate Medical Education is the lead sponsor of 46 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I-III
  • Scheduled for elective breast reduction surgery for non-oncological indications

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to provide written
  • History of chronic somatic or neuropathic pain
  • Current psychiatric disorders or ongoing treatment with antidepressant medications
  • Poorly controlled cardiovascular disease
  • Known allergy or intolerance to amide local anesthetics, including lidocaine and bupivacaine
  • Current alcohol abuse or substance use disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Erector spine plane block (ESPB)

    Bilateral ESPB performed before induction of anesthesia

    Procedure: Ultrasound - guided Erector Spine Plane Block (ESPB)

  • Experimental
    Lidocaine infusion

    Intravenous lidocaine bolus infusion started before induction of anesthesia and continued until the end of surgery

    Procedure: Intraoperative intravenous lidocaine infusion

Interventions

  • ProcedureUltrasound - guided Erector Spine Plane Block (ESPB)

    Bilateral ultrasound - guided ESPB will be performed before induction of anesthesia using 20 mL of 0.25% bupivacaine per side (total volume 40 mL).

  • ProcedureIntraoperative intravenous lidocaine infusion

    Patients will receive an intravenous lidocaine bolus of 1.5 mg/kg over 10 minutes before induction of anesthesia, followed by a continuous infusion of 1.5 mg/kg/h (0.15 mL/kg/h) until placement of the final skin suture.

06

What researchers measure

Primary outcomes

  1. Quality of recovery following breast reduction surgery

    Quality of Recovery score measured using the Quality of Recovery-15 questionnaire (QoR-15, 0 - 150, where 0 indicates very poor recovery and 150 indicates excellent recovery), assessed at least 24 hours after completion of surgery.

    Time frame: 48 hours

Secondary outcomes

  1. Postoperative opioid consumption

    Total consumption of rescue opioid analgesia (buprenorphine) during the first 24 postoperative hours

    Time frame: 24 hours

  2. Postoperative pain intensity 2 hours

    Pain intensity assessed by Numeric Rating Scale (0-10) 2 hours after completion of surgery

    Time frame: 2 hours

  3. Postoperative pain intensity 4 hours

    Pain intensity assessed by Numeric Rating Scale (0-10) 4 hours after completion of surgery

    Time frame: 4 hours

  4. Postoperative pain intensity 8 hours

    Pain intensity assessed by Numeric Rating Scale (0-10) 8 hours after completion of surgery

    Time frame: 8 hours

  5. Postoperative pain intensity 24 hours

    Pain intensity assessed by Numeric Rating Scale (NRS, 0-10, 0 indicating no pain and 10 worst pain imaginable) 24 hours after completion of surgery

    Time frame: 24 hours

  6. Postoperative pain intensity 48 hours

    Pain intensity assessed by Numeric Rating Scale (0-10) at 48 hours after completion of surgery

    Time frame: 48 hours

  7. Occurence of chronic postoperative and neuropathic pain 1 month

    Pain character assessed by Douleur Neuropathique 4 questionnaire (DN4, 0-10, where scores \>4 indicate neuropathic pain) 1 month after the surgery

    Time frame: 1 month

  8. Occurence of chronic postoperative and neuropathic pain 3 months

    Pain character assessed by Douleur Neuropathique 4 questionnaire (DN4, 0-10, where scores \>4 indicate neuropathic pain) 3 months after the surgery

    Time frame: 3 months

  9. Occurence of chronic postoperative and neuropathic pain 6 months

    Pain character assessed by Douleur Neuropathique 4 questionnaire (DN4, 0-10, where scores \>4 indicate neuropathic pain) 6 months after the surgery

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Centre of Postgraduate Medical Education,Department of Anesthesia and Intensive Care
    Warsaw, 01-813, Poland
    Recruiting
    • Bartosz Horosz, MD · Contact0048225841122
    • Bartosz Horosz, MD,PhD · Principal investigator
    • Anna Kociuba, MD · Sub investigator
    • Ada Bielejewska, MD · Sub investigator
    • Katarzyna Białowolska-Horosz, MD,PhD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jul 7, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
Centre of Postgraduate Medical Education,Department of Anesthesia and Intensive Care is now Recruiting
Oct 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Centre of Postgraduate Medical Education,Department of Anesthesia and Intensive Care · Warsaw, PolandContact added •••1122Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    Centre of Postgraduate Medical Education,Department of Anesthesia and Intensive Care is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centre of Postgraduate Medical Education,Department of Anesthesia and Intensive Care · Warsaw, PolandContact added •••1122Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07687069
Lead sponsor
Centre of Postgraduate Medical Education
Responsible party
Bartosz Horosz, MD (MD,PhD, Centre of Postgraduate Medical Education) — Principal investigator
First posted
Jul 7, 2026
Start date
Jul 1, 2026
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Bartosz Horosz, MD,PhD
Contact
bartosz.horosz@gmail.com
0048225841122
Katarzyna Białowolska-Horosz, MD,PhD
Contact
Małgorzata Malec-Milewska, MD, Prof.
study chair · Department of Anesthesia and Intensive Care, Orlowski Hospital, Warsaw

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion